UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to ___________

Commission File Number 0-51481
graphic
STRATA SKIN SCIENCES, INC.
(Exact name of registrant as specified in its charter)

 
Delaware
(State or other jurisdiction
of incorporation or organization)
 
13-3986004
(I.R.S.  Employer
Identification No.)
 

5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044
(Address of principal executive offices, including zip code)

(215) 619-3200
(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Exchange Act:
 
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SSKN
The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant: (i) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (ii) has been subject to such filing requirements for the past 90 days.
Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
 
Accelerated filer ☐
 
 
Non-accelerated filer
 
Smaller reporting company
 
 
Emerging growth company
     

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes   No ☒

The number of shares outstanding of the issuer’s common stock as of November 4, 2022 was 34,723,046 shares.


STRATA SKIN SCIENCES, INC.

TABLE OF CONTENTS

Part I. Financial Information:
PAGE
       
 
ITEM 1.  Financial Statements:
 
 
a.
1
       
 
b.
2
       
 
c.
3
       
 
d.
 4
       
 
e.
5
       
 
f.
6
       
 
24
       
 
33
       
 
33
       
 
       
 
34
       
 
34
       
 
35
       
 
35
       
 
35
       
 
35
       
 
35
       
   
36
       
   
E-31.1

PART I – Financial Information

ITEM 1.  Financial Statements

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

   
September 30, 2022
   
December 31, 2021
 
Assets
 
(unaudited)
       
Current assets:
           
Cash and cash equivalents
 
$
7,454
   
$
12,586
 
Restricted cash
    1,361       -  
Accounts receivable, net of allowance for doubtful accounts of $299 and $275 at September 30, 2022 and December 31, 2021, respectively
   
3,655
     
3,433
 
Inventories
   
5,662
     
3,489
 
Prepaid expenses and other current assets
   
621
     
462
 
Total current assets
   
18,753
     
19,970
 
                 
Property and equipment, net
   
6,566
     
6,883
 
Operating lease right-of-use assets
   
836
     
638
 
Intangible assets, net
   
18,110
     
10,083
 
Goodwill
   
8,803
     
8,803
 
Other assets
   
167
     
216
 
Total assets
 
$
53,235
   
$
46,593
 
                 
Liabilities and Stockholders’ Equity
               
Current liabilities:
               
Accounts payable
 
$
4,369
   
$
2,822
 
Accrued expenses and other current liabilities
   
6,075
     
6,377
 
Deferred revenues
    2,968
      3,285
 
Current portion of operating lease liabilities
   
246
     
318
 
Current portion of contingent consideration
   
500
     
-
 
Total current liabilities
   
14,158
     
12,802
 
                 
Long-term debt
   
7,435
     
7,319
 
Deferred revenues and other liabilities
    280
      400
 
Deferred tax liability
   
266
     
266
 
Operating lease liabilities net of current portion
   
674
     
392
 
Contingent consideration, net of current portion
   
8,622
     
-
 
Total liabilities
   
31,435
     
21,179
 
                 
Commitments and contingencies (Note 14)
           
     
     
 
Stockholders’ equity:
               
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding
   
-
     
-
 
Common stock, $0.001 par value, 150,000,000 shares authorized; 34,723,046 and 34,364,679 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively
   
35
     
34
 
Additional paid-in capital
   
248,833
     
247,059
 
Accumulated deficit
   
(227,068
)
   
(221,679
)
Total stockholders’ equity
   
21,800
     
25,414
 
Total liabilities and stockholders’ equity
 
$
53,235
   
$
46,593
 

The accompanying notes are an integral part of these condensed consolidated financial statements.

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)

   
For the Three Months Ended
September 30,
 
   
2022
   
2021
 
Revenues, net
 
$
9,413
   
$
7,711
 
Cost of revenues
   
3,614
     
2,335
 
Gross profit
   
5,799
     
5,376
 
                 
Operating expenses:
               
Engineering and product development
   
216
     
371
 
Selling and marketing
   
3,754
     
3,295
 
General and administrative
   
2,615
     
2,175
 
     
6,585
     
5,841
 
                 
Loss from operations
   
(786
)
   
(465
)
Other income (expense):
               
Interest expense
   
(244
)
   
(53
)
Interest income
    35       1  
      (209 )     (52 )
Loss before income taxes
   
(995
)
   
(517
)
Income tax expense
   
-
     
(4
)
Net loss
 
$
(995
)
 
$
(521
)
                 
Net loss per share of common stock, basic and diluted
  $ (0.03 )   $ (0.02 )
                 
Weighted average shares of common stock outstanding, basic and diluted
    34,723,046       34,150,438  

The accompanying notes are an integral part of these condensed consolidated financial statements.

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts)
(unaudited)

   
For the Nine Months Ended
September 30,
 
   
2022
   
2021
 
Revenues, net
 
$
25,559
   
$
20,920
 
Cost of revenues
   
10,639
     
7,070
 
Gross profit
   
14,920
     
13,850
 
                 
Operating expenses:
               
Engineering and product development
   
588
     
1,158
 
Selling and marketing
   
11,516
     
9,387
 
General and administrative
   
7,599
     
7,085
 
     
19,703
     
17,630
 
                 
Loss from operations
   
(4,783
)
   
(3,780
)
                 
Other income (expense):
               
Gain on debt extinguishment
    -       2,028  
Interest expense
    (651 )     (109 )
Interest income
    45       16  
      (606 )     1,935  
                 
Loss before income taxes
   
(5,389
)
   
(1,845
)
Income tax expense
   
-
     
(12
)
Net loss
 
$
(5,389
)
 
$
(1,857
)
                 
Net loss per share of common stock, basic and diluted
  $ (0.16 )   $ (0.05 )
                 
 Weighted average shares of common stock outstanding, basic and diluted     34,708,606
      33,944,321
 

The accompanying notes are an integral part of these condensed consolidated financial statements.

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Changes in Stockholders’ Equity
For the Nine Months Ended September 30, 2022 and 2021
(in thousands, except share amounts)
(unaudited)
 
   
Common Stock
   
Additional Paid-In
   
Accumulated
    Total Stockholders’  
   
Shares
   
Amount
   
Capital
   
Deficit
   
Equity
 
Balance at January 1, 2022
   
34,364,679
   
$
34
   
$
247,059
   
$
(221,679
)
 
$
25,414
 
Stock-based compensation
   
-
     
-
     
368
     
-
     
368
 
Issuance of common stock for acquisition
   
358,367
     
1
      499
      -
     
500
 
Net loss
   
-
     
-
     
-
     
(2,502
)
   
(2,502
)
Balance at March 31, 2022
   
34,723,046
     
35
     
247,926
     
(224,181
)
   
23,780
 
Stock-based compensation
    -
      -
     
452
     
-
     
452
 
Net loss
   
-
     
-
     
-
     
(1,892
)
   
(1,892
)
Balance at June 30, 2022
   
34,723,046
   

35
   

248,378
   

(226,073
)
 

22,340
 
Stock-based compensation
    -       -       455       -       455  
Net loss
    -       -       -       (995 )     (995 )
Balance at September 30, 2022     34,723,046     $ 35     $ 248,833     $ (227,068 )   $ 21,800  

   
Common Stock
   
Additional Paid-In
   
Accumulated
    Total Stockholders’  
   
Shares
   
Amount
   
Capital
   
Deficit
   
Equity
 
Balance at January 1, 2021
   
33,801,045
   
$
34
   
$
244,831
   
$
(218,973
)
 
$
25,892
 
Stock-based compensation
   
-
     
-
     
662
     
-
     
662
 
Issuance of restricted stock
   
16,260
     
-
     
-
     
-
     
-
 
Net loss
   
-
     
-
     
-
     
(2,418
)
   
(2,418
)
Balance at March 31, 2021
   
33,817,305
     
34
     
245,493
     
(221,391
)
   
24,136
 
Stock-based compensation
   
-
     
-
     
581
      -      
581
 
Issuance of restricted stock
   
71,934
     
-
     
-
      -      
-
 
Net income
   
-
     
-
     
-
     
1,082
     
1,082
 
Balance at June 30, 2021
   
33,889,239
   

34
   

246,074
   

(220,309
)
 

25,799
 
Stock-based compensation
    -       -       320       -       320  
Exercise of stock options
    329,076       -       -       -       -  
Issuance of restricted stock
    146,364       -       -       -       -  
Issuance of warrants
    -       -       585       -       585  
Net loss
    -       -       -       (521 )     (521 )
Balance at September 30, 2021     34,364,679     $ 34     $ 246,979     $ (220,830 )   $ 26,183  

The accompanying notes are an integral part of these condensed consolidated financial statements.

STRATA Skin Sciences, Inc. and Subsidiary
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

   
For the Nine Months Ended
September 30,
 
   
2022
   
2021
 
Cash flows from operating activities:
           
Net loss
 
$
(5,389
)
 
$
(1,857
)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
               
Amortization of intangible assets
   
2,155
     
1,113
 
Amortization of operating lease right-of-use assets
   
248
     
261
 
Depreciation and amortization
    1,816       1,576  
Amortization of deferred financing costs and debt discount
    116       -  
Provision (recoveries) for doubtful accounts
   
24
     
(26
)
Stock-based compensation
   
1,275
     
1,563
 
Loss on disposal of property and equipment
    52       73  
Gain on debt extinguishment
    -       (2,028 )
Deferred taxes
   
-
     
12
 
Changes in operating assets and liabilities:
               
Accounts receivable
   
(246
)
   
(181
)
Inventories
   
(1,616
)
   
219
 
Prepaid expenses and other assets
   
(110
)
   
(243
)
Accounts payable
   
1,547
     
(284
)
Accrued expenses and other liabilities
   
(267
)
   
858
 
Deferred revenues
   
(472
)
   
58
 
Operating lease liabilities
   
(236
)
   
(275
)
Net cash (used in) provided by operating activities
   
(1,103
)
   
839
 
                 
Cash flows from investing activities:                
Purchase of property and equipment
    (2,037 )     (2,523 )
Cash paid in connection with TheraClear asset acquisition
    (631 )     -  
Cash paid in connection with Ra Medical asset acquisition
    -       (3,473 )
Net cash used in investing activities
    (2,668 )     (5,996 )
                 
Cash flows from financing activities:                
Proceeds from  long-term debt
    -       8,000  
Payment of deferred financing costs
    -       (133 )
Repayment of note payable
    -       (7,275 )
Repayment of long-term debt
    -       (500 )
Net cash provided by financing activities
    -       92  
                 
Net decrease in cash, cash equivalents and restricted cash
   
(3,771
)
   
(5,065
)
Cash, cash equivalents and restricted cash, beginning of period
   
12,586
     
18,112
 
 
               
Cash, cash equivalents and restricted cash, end of period
 
$
8,815
   
$
13,047
 
                 
Cash and cash equivalents
 
$
7,454
   
$
13,047
 
Restricted cash
   
1,361
     
-
 
   
$
8,815
   
$
13,047
 
Supplemental disclosure of cash flow information:
               
Cash paid for interest
 
$
523
   
$
109
 
Supplemental disclosure of non-cash operating, investing and financing activities:
               
Change in operating lease right-of-use assets and liability due to amended lease
  $ 446     $ -  
Inventories acquired in connection with TheraClear asset acquisition
  $ 71     $ -  
Intangible assets acquired in connection with TheraClear asset acquisition   $ 10,182     $ -  
Contingent consideration issued in connection with TheraClear asset acquisition   $ 9,122     $ -  
Common stock issued in connection with TheraClear asset acquisition
  $ 500     $ -  
Transfer of property and equipment to inventories   $ 486     $ -  
Fair value of warrants issued in connection with debt   $ -     $ 585  
Assumed deferred revenue in connection with Ra Medical asset acquisition   $ -     $ 1,841  

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)

 

Note 1
The Company:

Background
STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear Acne Treatment Device to broaden its opportunities with expansion potential in the acne care market. The Company markets the device under the brand name TheraClear® X.

The XTRAC is an ultraviolet light excimer laser system utilized to treat psoriasis, vitiligo and other skin diseases. The XTRAC excimer laser system received clearance from the United States Food and Drug Administration (the “FDA”) in 2000. As of September 30, 2022, there were 899 XTRAC systems placed in dermatologists’ offices in the United States and 39 systems internationally under the Company’s recurring revenue business model. The XTRAC systems deployed under the recurring revenue model generate revenue on a per procedure basis or include a fixed payment over an agreed upon period with a capped number of treatments, which if exceeded would incur additional fees. The per-procedure charge is inclusive of the use of the system and the services provided by the Company to the customer, which includes system maintenance and other services. The VTRAC Excimer Lamp system, offered in addition to the XTRAC system internationally, provides targeted therapeutic efficacy demonstrated by excimer technology with a lamp system.

The Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma.

The TheraClear® Acne Clearing System combines intense pulse light with vacuum (suction) for the treatment of mild to moderate inflammatory acne (including acne vulgaris), comedonal acne and pustular acne.

Since 2019, the Company has been transitioning its international dermatology procedures equipment sales through its master distributor to a direct distribution model for equipment sales and recurring revenue on a country-by-country basis, primarily in the Middle East and Asia.

In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which became a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. In addition, the pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices which are our primary customers. While many offices reopened, some practices closed and never reopened, and the ongoing impact of the COVID-19 pandemic and its variants on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames, will depend on future developments, including the duration and ongoing spread of the COVID-19 outbreak and its variants, continued or renewed restrictions on business operations and transportation, any governmental and societal responses thereto, including legislative or regulatory changes as well as the percentage of the populace vaccinated and the effectiveness of COVID-19 vaccines and the continued impact on worldwide economic and geopolitical conditions and inflation, all of which are uncertain and cannot be predicted.

Domestically, as the procedures for which the Company’s devices are used are elective in nature; and as social distancing, travel restrictions, and other restrictions became prevalent in the United States, this had a negative impact on the Company’s recurring revenue model and its financial position and cash flow. The virus has disrupted the supply chains world-wide which the Company depends upon to provide a steady source of components to manufacture and repair the Company’s devices. To mitigate the impact of COVID-19, the Company took a variety of measures to ensure the availability and functioning of its critical infrastructure by implementing business continuity plans. To promote the safety and security of its employees, while complying with various government mandates including work-from-home arrangements and social-distancing initiatives to reduce the transmission of COVID-19, the Company is complying with federal and local regulations at its facilities. In addition, the Company created and executed programs utilizing its direct-to-consumer advertising and call center to contact patients and partner clinics to restart the Company’s partners’ businesses. In October 2021, the Company implemented a policy whereby all Company employees are required to be vaccinated or complete weekly COVID-19 testing.

See Note 2, Liquidity for discussion on Company liquidity.

6

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Supply chain disruptions which began during the pandemic have continued and may continue for the foreseeable future. While the Company’s operations have not been materially impacted by the general trends in supply chain problems, the Company continues to monitor and assess potential risks.

Basis of Presentation:

Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned, inactive subsidiary in India. All significant intercompany balances and transactions have been eliminated in consolidation.

Unaudited Interim Condensed Consolidated Financial Statements
The accompanying unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. These condensed consolidated statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2021 has been derived from the audited consolidated financial statements at that date. Operating results and cash flows for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2022 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”), and other forms filed with the SEC from time to time. Dollar amounts included herein are in thousands, except share and per share data and number of lasers.

Reclassifications
Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s condensed consolidated financial position, results of operations, or cash flows.

Significant Accounting Policies
The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the Company’s 2021 Form 10-K, and there have been no changes to the Company’s significant accounting policies during the nine months ended September 30, 2022.

Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of September 30, 2022, the more significant estimates include revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of acquired intangible assets, state sales and tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets.

Restricted Cash
As discussed more fully in Note 14, an administrative state judge in the State of New York issued an opinion in January 2021 finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. The relevant taxing authority filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, on May 6, 2022, the Company received a written decision from the State of New York Tax Appeals Tribunal (“Tribunal”) overturning the favorable sales tax determination of the administrative law judge. The Company filed an appeal of the Tribunal’s decision, and posted the required appellate bond requiring the posting of cash collateral, with the New York State Appellate Division, and is awaiting for the appellate court to set a briefing and oral argument schedule. The cash collateral is recorded as restricted cash on the condensed consolidated balance sheet. As of September 30, 2022, the Company had a restricted cash balance of $1,361.

7

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Fair Value Measurements
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 
Level 1 – quoted market prices in active markets for identical assets or liabilities.
 
Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 
Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

The fair values of cash and cash equivalents and restricted cash are based on their respective demand values, which are equal to the carrying values. The carrying values of all short-term monetary assets and liabilities are estimated to approximate their fair values due to the short-term nature of these instruments. As of September 30, 2022 and December 31, 2021, the carrying value of the Company’s long-term debt approximated its fair value due to its variable interest rate.

Net Loss Per Share
Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of September 30, 2022 and 2021, as they would be anti-dilutive:
 
    September 30,
 
 
  2022     2021  
Restricted stock units
    278,004       144,497  
Stock options
    4,544,714       3,963,889  
Common stock warrants
    373,626       373,626  
Total
    5,196,344       4,482,012  

Accounting Pronouncements Recently Adopted
In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, Earnings per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges or Freestanding Equity-Classified Written Call Options. The pronouncement outlines how an entity should account for modifications made to equity-classified written call options, including stock options and warrants to purchase the entity’s own common stock. The guidance in the ASU requires an entity to treat a modification of an equity-classified written call option that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the equity-classified written call option or as termination of the original option and issuance of a new option. The guidance is effective prospectively for fiscal years beginning after December 15, 2021. The adoption of this guidance on January 1, 2022 did not have a material effect on the condensed consolidated financial statements.

8

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Recent Accounting Pronouncements Not Yet Adopted
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended subsequently by ASUs 2018-19, 2019-04, 2019-05, 2019-10, 2019-11 and 2020-03. The guidance in the ASUs requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used. The standard also establishes additional disclosures related to credit risks. This standard is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company does not believe this will have a material effect on its condensed consolidated financial statements.
 
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. These pronouncements provide temporary optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships to ease the financial reporting burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. The transition period for adopting these ASUs is March 2020 through December 31, 2022. The Company continues to evaluate the temporary expedients and options available under this guidance and the effects of these pronouncements and, as the Company does not have any hedging activities, does not believe this will have a material effect on its condensed consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share (EPS) calculations in certain areas. The guidance is effective beginning after December 15, 2023 and early adoption is permitted. The Company does not currently engage in contracts covered by this guidance and does not believe it will have a material effect on the Company’s condensed consolidated financial statements, but it could in the future.

Note 2
Liquidity:
 
The Company has been negatively impacted by the ongoing COVID-19 pandemic, has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate, was required to restrict cash for potential sales tax liabilities (see Notes 1 and 14) and refinanced its debt at a lower interest rate. During the COVID-19 pandemic, the Company received cash proceeds from a Paycheck Protection Program (“PPP”) loan, which was forgiven, and an Economic Injury Disaster Loan (the “EIDL loan”) that was repaid at the time the Senior Term Facility was entered into with MidCap Financial Trust in September 2021 (Note 9). Additionally, in October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to $11,000 of its common stock in registered “at-the-market” offerings. Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of its products, will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these unaudited interim condensed consolidated financial statements. However, market conditions, including the negative impact of the ongoing COVID-19 outbreak on the financial markets, supply chain disruptions and rising interest rates, could interfere with the Company’s ability to access financing and on favorable terms.

Note 3 
Revenue Recognition:
 
Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term period specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

9

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Revenues from the sales of the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

 
identification of the contract, or contracts, with a customer;
 
identification of the performance obligations in the contract;
 
determination of the transaction price;
 
allocation of the transaction price to the performance obligations in the contract; and
 
recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from the sales of dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international recurring revenue customers as of September 30, 2022 :

Remaining 2022
 
$
313
 
2023
   
1,193
 
2024
   
835
 
2025
   
218
 
2026
   
4
 
Total
 
$
2,563
 

Remaining performance obligations related to Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties but exclude any equipment accounted for as leases. As of September 30, 2022, the aggregate amount of the transaction price allocated to remaining performance obligations was $583 and the Company expects to recognize $358 of the remaining performance obligations within one year and the balance over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.
 
10

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Contract liabilities primarily relate to extended warranties where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of stand-alone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of September 30, 2022, the $358 of short-term contract liabilities is presented as deferred revenues and the $225 of long-term contract liabilities is presented within deferred revenues and other liabilities on the condensed consolidated balance sheet. For the three months ended September 30, 2022 and 2021, the Company recognized $152 and $19, respectively, as revenue from amounts classified as contract liabilities (e.g. deferred revenues) as of December 31, 2021 and 2020. For the nine months ended September 30, 2022 and 2021, the Company recognized $790 and $73, respectively, as revenue from amounts classified as contract liabilities (e.g. deferred revenues) as of December 31, 2021 and 2020.
 
With respect to contract acquisition costs, the Company applies the practical expedient and expenses these costs immediately.

Note 4
Acquisitions:

TheraClear Asset Acquisition
In January 2022, the Company acquired certain assets related to the TheraClear Devices from Theravant Corporation (“Theravant”). The TheraClear asset acquisition will allow the Company to further develop, commercialize and market the TheraClear Devices that are used for acne treatment, as well as advance the TheraClear technology into multiple other devices that can be used to treat a range of additional indications.

The Company made an upfront cash payment of $500 and issued to Theravant 358,367 shares of common stock with an aggregate value of $500 as of the closing date in connection with the TheraClear asset acquisition. Theravant is eligible to receive up to $3,000 in future earnout payments upon the achievement of certain annual net revenue milestones, up to $20,000 in future royalty payments based upon a percentage of gross profit from future domestic sales ranging from 10-20%, 25% of gross profit from international sales over the subsequent four-year period, and up to $1,000 in future milestone payments upon the achievement of certain development and commercialization related targets.

The Company determined this transaction represented an asset acquisition as substantially all of the value was in the TheraClear technology intangible asset as defined by ASC 805, Business Combinations (“ASC 805”).

The purchase price was allocated, on a relative fair value basis, to the technology intangible asset and acquired inventories as follows:

Consideration:
     
Cash payment
 
$
500
 
Common stock issued
    500
 
Transaction costs
   
131
 
Contingent consideration     9,122
 
Total consideration
 
$
10,253
 
         
Assets acquired:
       
Technology intangible asset
  $
10,182
 
Inventories
 
71
 
Total assets acquired
 
$
10,253
 

11

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
The technology intangible asset is being amortized on a straight-line basis over a period of ten years, to be updated for subsequent changes in the contingent consideration that is allocated to its carrying value. The intangible asset was valued using the relief from royalty method. Significant assumptions used in the relief from royalty method include a 14.5% weighted average cost of capital and 15.0% of revenues for the royalty rate. The net book value of acquired inventories approximated its fair value. To calculate the fair value of the earnout using Monte Carlo simulations, Company projections were utilized to develop expected revenues and gross profits based on the risk inherent in the projections using the Geometric-Brownian motion for the earnout periods and related earnout payments. Significant assumptions used in the Geometric-Brownian motion analysis include projected revenues, projected gross profit, risk free rate of return of 1.6%, revenue volatility of 45.0%, and a cost of equity of 10.5%. Due to uncertainties associated with the development of a new product line and the use of estimates and assumptions to determine the fair value of the contingent consideration, the amount ultimately paid in connection with the earnout may differ from the estimated fair value at the acquisition date. A revaluation of the contingent consideration would only be required if there is a significant change to the underlying valuation assumptions. The contingent consideration will be adjusted when the contingency is resolved and the consideration is paid or becomes payable. Any difference between the cash payment and the amount accrued for contingent consideration will result in an adjustment to the technology intangible asset. Contingent consideration expected to be paid within the next year, which consists of $500 paid in October 2022, is classified as current on the condensed consolidated balance sheet.

Pharos Asset Acquisition
In August 2021, the Company acquired certain assets and liabilities related to the U.S. dermatology Pharos business from Ra Medical Systems, Inc. (“Ra Medical”). Ra Medical’s Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma. The acquisition of these assets and liabilities allows the Company to market its full business solutions to Ra Medical’s existing customer base comprised of 400 dermatology practices offering opportunities to increase its recurring revenue base and a pathway to gain additional placements for the Company’s XTRAC excimer laser system.

The purchase price of $3,700 was paid in cash at the time of acquisition. In addition, the Company assumed certain extended warranty service contracts associated with acquired laser system products. Concurrent with the purchase of the net assets, the Company and Ra Medical entered into a services agreement whereby Ra Medical will provide certain transitional services for the Company as it integrates the acquired assets into the Company. The Company determined this transaction represented an asset acquisition as substantially all of the value was in the acquired customer list intangible asset as defined by ASC 805. The purchase price was allocated, on a relative fair basis, to the acquired inventories, customer lists and deferred revenue as follows:

Consideration:
     
Cash payment
 
$
3,700
 
Transaction costs
   
57
 
Total consideration
 
$
3,757
 
         
Assets acquired:
       
Inventories
 
$
284
 
Customer lists intangible asset
   
5,314
 
Total assets acquired
 

5,598
 
         
Liabilities assumed:
       
Deferred revenues – service contracts
 

1,841
 
Total liabilities assumed
 

1,841
 
         
Net assets acquired
 
$
3,757
 



The customer lists intangible asset is being amortized on a straight-line basis over a period of 12 years. As the transaction was accounted for as an asset acquisition, the Company allocated consideration paid to the inventories acquired and the deferred revenues assumed with the remaining consideration paid allocated to the customer lists intangible asset, which also equals its estimated fair value. The intangible asset was valued using an excess earnings model. Significant assumptions used in the excess earnings model include estimated customer sales growth, customer attrition, and weighted average cost of capital of 3%, 5% and 17%, respectively.

12

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Note 5
Inventories:
 
Inventories consist of the following:
 
   
September 30, 2022
   
December 31, 2021
 
Raw materials and work-in-process
 
$
5,426
   
$
3,201
 
Finished goods
   
236
     
288
 
Total inventories
 
$
5,662
   
$
3,489
 

Work-in-process is immaterial, given the Company’s typically short manufacturing cycle and therefore, is included with raw materials.
 
Note 6
Property and Equipment, net:
 
Property and equipment consist of the following:
 
   
September 30, 2022
   
December 31, 2021
 
Lasers placed-in-service
 
$
27,360
   
$
25,949
 
Equipment, computer hardware and software
   
293
     
238
 
Furniture and fixtures
   
235
     
213
 
Leasehold improvements
   
80
     
254
 
     
27,968
     
26,654
 
Accumulated depreciation and amortization
   
(21,402
)
   
(19,771
)
Property and equipment, net
 
$
6,566
   
$
6,883
 

Depreciation and amortization expense was $592 and $575 for the three months ended September 30, 2022 and 2021, respectively. Depreciation and amortization expense was $1,816 and $1,576 for the nine months ended September 30, 2022 and 2021, respectively.
 
13

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Note 7
Intangible Assets, net:
 
Intangible assets consist of the following as of September 30, 2022:
 
   
Balance
   
Accumulated
Amortization
   
Intangible
Assets, net
 
Core technology
 
$
5,700
   
$
(4,133
)
 
$
1,567
 
Product technology
   
12,182
     
(2,764
)
   
9,418
 
Customer relationships
   
6,900
     
(5,003
)
   
1,897
 
Tradenames
   
1,500
     
(1,088
)
   
412
 
Pharos customer lists     5,314
      (498 )     4,816
 
   
$
31,596
   
$
(13,486
)
 
$
18,110
 

Intangible assets consist of the following as of December 31, 2021:

   
Balance
   
Accumulated
Amortization
   
Intangible
Assets, net
 
Core technology
 
$
5,700
   
$
(3,705
)
 
$
1,995
 
Product technology
   
2,000
     
(2,000
)
   
-
 
Customer relationships
   
6,900
     
(4,485
)
   
2,415
 
Tradenames
   
1,500
     
(975
)
   
525
 
Pharos customer lists
    5,314
      (166 )     5,148
 
   
$
21,414
   
$
(11,331
)
 
$
10,083
 

Amortization expense was $719 and $408 for the three months ended September 30, 2022 and 2021, respectively. Amortization expense was $2,155 and $1,113 for the nine months ended September 30, 2022 and 2021, respectively.
 
Finite-lived intangible assets are tested for impairment when events or changes in circumstances indicate that the carrying value of the asset group may not be recoverable. The Company recognizes an impairment loss when and to the extent that the recoverable amount of an asset group is less than its carrying value. There were no impairment charges for the three and nine months ended September 30, 2022 or 2021.

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years:
 
Remaining 2022
 
$
717
 
2023
   
2,871
 
2024
   
2,871
 
2025
   
2,166
 
2026
   
1,461
 

14

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
Note 8
Accrued Expenses and Other Current Liabilities:

Accrued expenses and other current liabilities consist of the following:

    September 30, 2022     December 31, 2021  
 
           
Warranty obligations
 
$
118
   
$
59
 
Compensation and related benefits
   
1,379
     
2,052
 
State sales, use and other taxes
   
3,742
     
3,697
 
Professional fees and other
   
836
     
569
 
Total accrued expenses and other current liabilities
 
$
6,075
   
$
6,377
 

Note 9
Long-term Debt:


Senior Term Facility
On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust, also acting as the administrative agent, and the lenders identified therein (“Senior Term Facility”). The Senior Term Facility provides for an $8,000 senior term loan that was drawn upon by the Company upon executing the agreement. Borrowings under the Senior Term Facility bear interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and mature on September 1, 2026, unless terminated earlier. The Company is obligated to make monthly interest-only payments through September 30, 2024. From October 1, 2024 to the date of maturity, the Company will make 24 equal monthly principal payments plus interest, and all borrowings are secured by substantially all of the Company’s assets. The Senior Term Facility was amended on January 10, 2022 to permit the acquisition of TheraClear Devices (Note 4).

The Company may voluntarily prepay the outstanding term loan, with such prepayment at least $5,000, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made within 12 months of September 30, 2021, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after September 30, 2021, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after September 30, 2021, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after September 30, 2021 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions. The Senior Term Facility also contains a number of negative covenants that subject the Company to certain exceptions and waivers and restrictions, as defined in the agreement. In addition, the Senior Term Facility contains a quarterly financial covenant that requires the Company to have a specified minimum amount of net revenue for the trailing 12-month period, with compliance measured on the last day of each fiscal quarter beginning on September 30, 2021. At September 30, 2022, the minimum net revenue threshold was $27,000. The minimum net revenue threshold will increase to $30,000 by December 31, 2023. At September 30, 2022, the Company was in compliance with all financial and nonfinancial covenants within the Senior Term Facility.

The Senior Term Facility contains customary indemnification obligations and customary events of default, including, among other things, (i) nonpayment, (ii) breach of warranty, (iii) nonperformance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (iv) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (xi) regulatory matters, (xii) failure to remain a publicly traded company and (xiii) material adverse event. Where an event of default arises from certain bankruptcy events, the commitments shall automatically and immediately terminate and the principal of, and interest then outstanding on, all of the loans shall become immediately due and payable. Subject to certain notice requirements and other conditions, upon the occurrence of other events of default, including the occurrence of a condition having or reasonably likely to have a material adverse effect, commitments may be terminated and the principal of, and interest then outstanding on, all of the loans may become immediately due and payable. On September 30, 2022, no event of default had occurred and the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and was remote.

15

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
In connection with entering into the Senior Term Facility, the Company issued an affiliate of the lender a warrant to purchase 373,626 shares of the Company’s common stock at an initial exercise price of $1.82 per share. The warrants are equity classified and are exercisable at any time on or prior to the tenth anniversary of their issue date. The estimated fair value of the warrants was $585 and determined using the Black-Scholes option pricing model. The key assumptions used in the Black-Scholes option pricing model were (i) an expected term of ten years, (ii) expected volatility of 88.6%, (iii) a risk-free rate of 1.50% and (iv) no estimated dividend yield. In addition, the Company incurred third party costs and lender fees of $133. The proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrants and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $565 as of September 30, 2022. The Company recognized interest expense of $244 and $651 during the three and nine months ended September 30, 2022, of which $40 and $116 was related to the amortization of the debt discount for the three and nine months ended September 30, 2022.


Future minimum principal payments at September 30, 2022 are as follows:

2024
 
$
1,000
 
2025
   
4,000
 
2026
   
3,000
 
Total
 
$
8,000
 

Note 10
Stock-based Compensation:

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of September 30, 2022, there were 3,123,706 shares of common stock remaining available for issuance for awards under the 2016 Plan.
 
The Company measures stock‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded stock‑based compensation expense of $455 and $320 for the three months ended September 30, 2022 and 2021, respectively, and $1,275 and $1,563 for the nine months ended September 30, 2022 and 2021, respectively, and stock-based compensation was included within general and administrative expenses in the accompanying condensed consolidated statements of operations.
Stock Options

The following table summarizes stock option activity for the nine months ended September 30, 2022:

   
Number of
shares
   
Weighted
average
exercise price
per share
   
Weighted
average
remaining
contractual
term (years)
 
Outstanding at January 1, 2022
   
3,938,613
   
$
1.90
       
Granted
   
970,000
   
$
1.43
       
Exercised
   
(15,000
)
 
$
1.29
       
Forfeited and expired
   
(348,899
)
 
$
2.97
       
Outstanding at September 30, 2022     4,544,714     $ 1.72       8.3  
Exercisable at September 30, 2022     1,771,742     $ 1.88       7.4  
Vested and expected to vest
    4,544,714     $ 1.72       8.3  

The weighted‑average grant date fair value of options granted was $1.07 per share during the nine months ended September 30, 2022. As of September 30, 2022, the total unrecognized compensation expense related to unvested stock option awards was $2,678, which the Company expects to recognize over a weighted‑average period of approximately 2.2 years. There was no aggregate intrinsic value of options outstanding and options exercisable at September 30, 2022.

16

Table of Contents

STRATA Skin Sciences, Inc. and Subsidiary
Notes to Unaudited Condensed Consolidated Financial Statements
(in thousands, except share and per share amounts and number of lasers)
(unaudited)
For the nine months ended September 30, 2022, the fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:
Expected volatility